Prevalence of Faecal Bacteriophage in Patients With Digestive Symptoms
Launched by CENTRAL HOSPITAL, NANCY, FRANCE · Jul 24, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the presence of specific viruses called fecal bacteriophages in people who have digestive symptoms, such as gastroenteritis. The researchers want to find out how common these viruses are in stool samples from individuals who show signs of digestive issues. They will look at both the amount of infectious fecal phages and their genetic material in the participants' stool. Additionally, the study aims to understand if certain factors, like having a healthy immune system or being immunocompromised, affect the presence of these viruses.
To participate in this trial, individuals must be between 18 and 60 years old and experiencing gastrointestinal symptoms that require stool testing while in the hospital. Importantly, participants will need to give their consent to use their data for the study. The trial is not yet recruiting participants, so there’s no need to worry about enrolling just yet. Overall, this research could help improve our understanding of digestive problems and the role of these viruses in such conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age between 18 and 60.
- • Persons having developed gastrointestinal symptoms justifying microbiological stool testing at the time of hospitalization.
- • Person having received full information on the organization of the research and not having objected to the use of this data
- Exclusion Criteria:
- • Persons covered by articles L. 1121-5, L. 1121-7 and L1121-8 of the French Public Health Code.
- • Pregnant or breast-feeding women,
- • Minors (not emancipated),
- • Adult subject to a legal protection measure (guardianship, curatorship, safeguard of justice),
- • Persons of full age who are unable to give their consent.
- • Persons deprived of their liberty by a judicial or administrative decision, persons under psychiatric care by virtue of articles L. 3212-1 and L. 3213-1.
About Central Hospital, Nancy, France
Central Hospital, located in Nancy, France, is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes. As a prominent clinical trial sponsor, the hospital is committed to conducting innovative studies across various therapeutic areas, fostering collaboration among multidisciplinary teams of healthcare professionals and researchers. With a strong emphasis on ethical standards and patient safety, Central Hospital leverages its state-of-the-art facilities and expertise to contribute to the development of cutting-edge treatments and enhance the overall quality of care within the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nancy, , France
Patients applied
Trial Officials
Cédric Hartard
Principal Investigator
CHRU Nancy
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported